Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from boosted protease inhibitor regimen to Biktarvy in virologically suppressed HIV-1 adults with resistance mutations
2018-004732-30Phase 4Unknown
- Sponsor
- University of Sussex
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of bictegravir + emtricitabine + tenofovir alafenamide in Human immunodeficiency virus infection type 1 (2 arms), sponsored by University of Sussex. Primary endpoint: HIV-1 RNA suppression at week 24. Status: unknown.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2018-004732-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004732-30.